This non-interventional study is to monitor use in real practice in Korea including adverse
events on Aromasin (Exemestane).
- - Postmenopausal women with breast cancer eligible for hormonal therapy.
- Pregnant breast-feeding premenopausal.
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center
Pfizer Clinical Trials Contact Center
call now email
Contact a representative by phone, email, or visiting the study website. Please see the references below: